Clasp Therapeutics

Clasp Therapeutics is dedicated to revolutionizing immuno-oncology through the development of cutting-edge T cell engagers (TCEs). Focusing on tumor-specific oncogenic driver mutations, Clasp Therapeutics is engineering next-generation TCEs designed to target and treat even the most challenging cancers.

Clasp Therapeutics is committed to creating highly personalized, off-the-shelf therapeutics by matching the specific characteristics of a patient’s immune system with the unique genetics of their tumor. This innovative approach is rooted in groundbreaking academic research from the labs of Bert Vogelstein and Drew Pardoll at Johns Hopkins University.

With the support of leading life sciences investors, including Catalio Capital Management, Third Rock Ventures, and Novo Holdings, Clasp Therapeutics is poised to make significant advancements in cancer treatment. We invite the management team at Clasp Therapeutics to create a customized and exclusive company showcase and product listing on our platform, further enhancing your visibility and commercial development.